ライフサイエンスコーパス: panretinal

1 pheral retinal NV severity and incidence and panretinal arteriole and venule tortuosity indexes (TI(a

2 the intent of generating a rapid noninvasive panretinal assessment of ocular inflammation.

3 entan admix both produced similar (P > 0.05) panretinal DeltaPo(2).

4 On day 20, the panretinal deltaPO2 of the room air-recovered group (125

5 The panretinal deltaPO2 value for the SOR group (87 +/- 5 mm

6 Also, control and diabetic LEW rat panretinal DeltaPO2(t1-ra) were lower (P < 0.05) than in

7 diabetic LEW rats, a supernormal (P < 0.05) panretinal DeltaPO2(t2-t1) was found that could be corre

8 ated a 63-year-old woman demonstrating acute panretinal dysfunction after intravitreous ocriplasmin i

9 Ocriplasmin injection may lead to acute panretinal dysfunction in some eyes, but the mechanism o

10 those with regressed ROP following bilateral panretinal laser photocoagulation (n = 37; median gestat

11 ive diabetic retinopathy has been managed by panretinal laser photocoagulation (PRP) for the past 40

12 Panretinal laser photocoagulation (PRP) was shown to be

13 ailable to all patients starting at month 3; panretinal laser was available as necessary.

14 7D (MBDL) or 35B to 53E (MBCU), and no prior panretinal or focal photocoagulation in at least one eye

15 gly support an association between subnormal panretinal oxygenation ability and increased NV risk in

16 occurred but with an unexpected decrease in panretinal oxygenation ability.

17 ance imaging (MRI) was used to determine the panretinal oxygenation response (deltaPO2, mm Hg) to a c

18 ing the period when lesions are present, the panretinal oxygenation response remained significantly (

19 s, a significant (P < 0.05) reduction in the panretinal oxygenation response was observed in the gala

20 s exhibit a grainy retina that progresses to panretinal patches of depigmentation.

21 bevacizumab, sub-Tenon's triamcinolone, and panretinal photocoagulation (PRP) after cataract surgery

22 termine the validity of self-report of prior panretinal photocoagulation (PRP) and focal photocoagula

23 Panretinal photocoagulation (PRP) for proliferative diab

24 Panretinal photocoagulation (PRP) is the standard treatm

25 betic retinopathy (PDR) in eyes treated with panretinal photocoagulation (PRP) or ranibizumab.

26 h newly diagnosed high-risk PDR treated with panretinal photocoagulation (PRP) using either argon gre

27 mab is a reasonable treatment alternative to panretinal photocoagulation (PRP) when managing prolifer

28 al treatments including PPV, injections, and panretinal photocoagulation (PRP), as well as visual acu

29 PDR based on graded fundus photographs, (2) panretinal photocoagulation (PRP), or (3) pars plana vit

30 d, though somewhat disorganized, as in human panretinal photocoagulation (PRP).

31 c retinopathy (PDR), previously treated with panretinal photocoagulation (PRP).

32 ovascularization is best managed by applying panretinal photocoagulation after the first appearance o

33 lar endothelial growth factor injections and panretinal photocoagulation are important to prevent neo

34 cluding visual acuity improvement, increased panretinal photocoagulation completion rates, and reduce

35 had vitreous hemorrhage from PDR precluding panretinal photocoagulation completion.

36 Panretinal photocoagulation is designed to increase reti

37 n with intravitreal anti-VEGF medication and panretinal photocoagulation may help to prevent addition

38 Panretinal photocoagulation or intravitreous ranibizumab

39 Panretinal photocoagulation treatments declined from 109

40 Panretinal photocoagulation was shown to be beneficial f

41 intravitreous injections of bevacizumab and panretinal photocoagulation were administered, the new v

42 nce, 4%; 95% CI, -4% to 13%) and of complete panretinal photocoagulation without vitrectomy by 16 wee

43 in eyes without PDR at baseline, (3) having panretinal photocoagulation, (4) experiencing vitreous h

44 rative diabetic retinopathy (PDR) usually is panretinal photocoagulation, an inherently destructive t

45 Treatment for PDR, panretinal photocoagulation, is inherently destructive a

46 des for intravitreal injection, focal laser, panretinal photocoagulation, laterality of procedure, ra

47 endothelial growth factor (VEGF) injection, panretinal photocoagulation, or both for retinal ischemi

48 especially in eyes that are nonresponsive to panretinal photocoagulation.

49 cludes placement or confirmation of complete panretinal photocoagulation.

50 Panretinal TI(a) and TI(v) were increased over control v

51 y associated with peripheral NV severity and panretinal TI(a).

52 s associated with peripheral NV severity and panretinal TI(a).

53 Panretinal TI(v) was not correlated with intraretinal io